[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
September 1969

Immunotherapy of Malignant Disease

Author Affiliations

Buffalo, NY
From the Department of Surgery, Roswell Park Memorial Institute, New York State Department of Health, Buffalo. Dr. Nadler is now at Jefferson Medical College, Department of Surgery, Philadelphia.

Arch Surg. 1969;99(3):376-381. doi:10.1001/archsurg.1969.01340150084016

The importance of host resistance and immunological factors in influencing the growth of tumors has been suspected for over 50 years.1 A great deal of experimental evidence has accumulated in the past two decades to support this thesis, and further studies in the immunologic field are now warranted on the basis of this evidence.

The mechanisms by which host cells inhibit cancer growth or destroy cancer cells is not completely understood. Much of the early experimental work was concerned with attempts to demonstrate circulating antibodies against malignant tissues, identify specific tumor antigens, and develop effective cancer vaccines. In 1953, Foley2 demonstrated specific antigenicity in a class of experimentally induced tumors induced by methylcholanthrene in syngeneic mice. He demonstrated that the removal of a growing transplant of an induced tumor was followed by resistance to subsequent challenge with the same tumor. These experiments have been confirmed many times and

First Page Preview View Large
First page PDF preview
First page PDF preview